There is evidence to suggest that elevated insulin-like growth factor-1 (IGF-1) levels in diabetic patients lead to an increase in cytokine and estrogen levels, an imbalance in adipokines, and hyperinsulinemia, thereby increasing the risk of ovarian cancer and impacting patients’ survival [17, 18]. Here, IGF1 is linked to ovarian carcinoma.